Trichostatin A (TSA) 化学構造
分子量: 302.4

高品質保証

カスタマーフィードバック(5)

MSDS

製品説明

  • Compare HDAC Inhibitors
    HDAC製品生物活性の比較
  • 研究分野
  • Combination Therapy
    併用療法
  • Trichostatin A (TSA)のメカニズム

製品の説明

生物活性

製品説明 Trichostatin A (TSA)は一種のHDAC阻害剤で、無細胞試験でIC50値が1.8 nM程度です。
ターゲット

HDAC

IC50

~1.8 nM [1]

In vitro試験 Trichostatin A inhibits the proliferation of eight breast carcinoma cell lines including MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, and SK-BR-3 with mean IC50 of 124.4 nM (range, 26.4-308.1 nM), with more potency against cell lines that express ERα than the ERα-negative cell lines. Trichostatin A inhibits HDAC activity similarly in all the breast cancer cell lines with mean IC50 of 2.4 nM (range, 0.6-2.6 nM), and results in pronounced histone H4 hyperacetylation. [1] Unlike Trapoxin (TPX) and Chlamydocin which potently inhibit HDAC1 or HDAC4 but not HDAC6, Trichostatin A inhibits these HDACs to a similar extent with IC50 of 6 nM, 38 nM, and 8.6 nM, respectively. [2] Trichostatin A (100 ng/mL) treatment induces the expression of transforming growth factor β type II receptor (TβRII) in MIA PaCa-2 cells through the recruitment of p300 and PCAF into a Sp1-NF-Y HDAC complex that binds the DNA element of TβRII promoter, which is associated with a concomitant acetylation of Sp1 and an overall decrease in the amount of HDAC associated with the complex. [4]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
HEK 293 NF\aVJRHfW6ldHnvckBCe3OjeR?= M2nvW|AvP87:TR?= NUPLcFBZOjSq MYPleIhidm:u MX;lcohidmOnczDFUoFEKGGlZYT5cIF1cW:wIHHu[EBqdmO{ZXHz[ZMhTU6jQzDhZpVv\GGwY3WgbY4hfGinIITveIFtKGOnbHygcJl{[XSnIHHu[EBifCC2aHWgZ4VtdCC|dYLmZYNm M4[xTVI2Pzh5MEe5
TE13 MXTGeY5kfGmxbjDBd5NigQ>? MXywMlPPxE1? NFKy[GszPGh? MWn1dE1z\We3bHH0[ZMhWkGVU1[1RUBt\X[nbB?= NVfTWo5IOjV3N{m2OlU>
TE13 NVL4V2M3SXCxcITvd4l{KEG|c3H5 MXuwMlPPxE1? M1jKN|I1cA>? MknDbY5pcWKrdIOgeIhmKGOnbHygdJJwdGmoZYLheIlwdg>? MlLBNlU2Pzl4NkW=
MEFs NWW5RYo3TnWwY4Tpc44hSXO|YYm= NEHB[I02|ryP MmqzNVZp M336dIlv[3KnYYPld{B1cGViRWDFR{BifHSjY3jt[Y51NCCWaYKg[IVtcX[ncomgZY5lKHSqZTDl[oZq[2mnbnP5JI9nKHCnZHXzeIFtKG[xcn3heIlwdg>? MoDONlU1QDJ4M{S=
SW480  NULJZ3FKTnWwY4Tpc44hSXO|YYm= MoLaNE4y|ryP NFy0c5M1QGh? NXnEZ24{TE2VTx?= MmqwdoV3\XK|ZYOgSW1V MkGzNlU1OzR7OUe=
PC3  MX;GeY5kfGmxbjDBd5NigQ>? M2nM[lAvOc7:TR?= NGjLb2o1QGh? MXHEUXNQ M3XPbpJmfmW{c3XzJGVOXA>? NHyyTWwzPTR|NEm5Oy=>
SW480  NHfpOGtHfW6ldHnvckBCe3OjeR?= NH\s[5kxNjIQvF2= MlW5OFhp NW\RVXNQTE2VTx?= M2PxXIF1fGWwdXH0[ZMhcW64YYPpc44h[W6mIH3p[5JifGmxbh?= M{D1clI2PDN2OUm3
PC3  NGPTOHVHfW6ldHnvckBCe3OjeR?= NFHldWIxNjIQvF2= MkLROFhp NUfGWHo5TE2VTx?= M4nadYF1fGWwdXH0[ZMhcW64YYPpc44h[W6mIH3p[5JifGmxbh?= MnXwNlU1OzR7OUe=
SW480  M1n6cGZ2dmO2aX;uJGF{e2G7 M3\KTlAvOc7:TR?= MVm0PIg> NYjpbmFQTE2VTx?= M{\3bolv\HWlZYOgbY5kemWjc3Wgc4YhUESDQ{GgZY5lKEiGQVOyJI9vKFOudXeg[4Vv\XNicILvcY91\XJ? MV:yOVQ{PDl7Nx?=
PC3  NIHOeI9HfW6ldHnvckBCe3OjeR?= M4iwclAvOc7:TR?= MUO0PIg> MXLEUXNQ M2XpOolv\HWlZYOgbY5kemWjc3Wgc4YhUESDQ{GgZY5lKEiGQVOyJI9vKFOudXeg[4Vv\XNicILvcY91\XJ? M{jYTFI2PDN2OUm3
A431 NVLvR3hjSXCxcITvd4l{KEG|c3H5 Mn3JNk8yOC93MD:xNFBvVQ>? NUHsfnFpPDiq MWnEUXNQ NUHOUGVucW6qaXLpeJMhfGinIHPlcIwh\3Kxd4To MnL2NlU{PzFyNkm=
A431 M1q4NGZ2dmO2aX;uJGF{e2G7 NHjPbnk2OG6P MVKyM|YwOTJxMkTo NEPBdWlFVVOR MlHIZYN1cX[jdHXzJJAzOSCjbnSgbY5pcWKrdIOgRXRHOyCneIDy[ZN{cW:w M2q5WFI2OzdzME[5
MDA-MB-231 NUewRZF7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUewMVYxOG6P NUDENGpIOjSq NXP3VXpsTE2VTx?= NV;aSmJnUUN3MDDv[kAyODCwTR?= NGrBZ4ozPTF7MkeyNS=>
MCF7 Mnr3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDIXGRUOC14MEDuUS=> MkfsNlRp M3jpN2ROW09? NFjFNlBKSzVyIH;mJFc2dk1? M2\CVFI2OTl{N{Kx
SKOV-3 MmOxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUexMVEx|ryP MX[yOIg> MmHhSG1UVw>? MoPsTWM2OCCxZjC1MlbPxE1? M3GwZVI2OTZ7NEmx
A549 NGjreXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjBS5hzOS1zMN88US=> M3PqdFI1cA>? M1n6NWROW09? M17GVWlEPTBib3[gN{4z|ryP NXLpSpBlOjVzNkm0PVE>
SKOV-3 NVrGRYFFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFrDcYoxNjFvMd88US=> MkfmOFhp M{ToTWROW09? NXrrZW5MUUN3MDDv[kAxNjgQvF2= MmDHNlUyPjl2OUG=
A549 NXjVU3UxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;ke4U4OC5zLUJOwG0> M1zhNlQ5cA>? MnzySG1UVw>? NETJWVZKSzVyIH;mJFAvOjkQvF2= NFXIW4MzPTF4OUS5NS=>
SKOV-3 MojXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYTnXoQ6OC5yMT2wMlnPxE1? MYq3Nog> NGjEbnlFVVOR NUfifVk6UUN3MDDv[kAxNjN{zszN MnrZNlUyPjl2OUG=
A549 M33pXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\ENE4xOS1yLkpOwG0> Mm\nO|Jp MUjEUXNQ NGnwXHdKSzVyIH;mJFAvODcQvF2= NIjyOGYzPTF4OUS5NS=>
HeLa M2TmWWZ2dmO2aX;uJGF{e2G7 M{PkclI2OG6P MW[xOog> MVfEUXNQ M1OyW4lv[3KnYYPld{BEYVBzQUGgcXJPSSCneIDy[ZN{cW:wwrC= Mnm3NlUyOTZ4OEi=
CNE2 MoThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjr[pl7OTByLU[wNI5O NXTEbI1uOjRxNEivO|Jp NVTacWRLcW6qaXLpeJMhfGinIIDyc4xq\mW{YYTpc44hcW5iYTD0bY1mNSCjbnSg[I9{\S2mZYDlcoRmdnRibXHucoVz Ml31NlQ6Pjl7MEG=
PC3 NX25ZZpmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3aNVAxNTFyMEDuUS=> NEHwZ3czPGh? M3zqXGlEPTBib3[gN|Axdk1? MVqyOFg2PDZ3OB?=
LNCaP NHvtfIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYWxNFAuOTByMH7N MmrqNlRp M2C5XWlEPTBib3[gN|Axdk1? NETDXYczPDh3NE[1PC=>
HeLa  MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLrdI4z|ryP NVzwV4NsPDiq MVvk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliYXLveZQhOjVn MnnONlQ5PDZzM{W=
HMEC-1  MknGSpVv[3Srb36gRZN{[Xl? M{\JWFMxOG6P M3HmbVI1cA>? MYHpcoNz\WG|ZYOg[ZhxemW|c3nvckBw\sLiVlXHSnI{yqCvUl7B MWOyOFcyODZ|MR?=
HeLa MUHGeY5kfGmxbjDBd5NigQ>? MYCxcW0> MVSwMlVp M4fqNoFjd2yrc3jld{B1cGVidH;0ZYwhUESDQzDhZ5Rqfmm2eR?= MWGyOFcxPzR5NB?=
ACP02 NXjoU4lvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXKyOVAwOzVyL{WwNI5O NXHZOmhZOjSq NVexT2tZ\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JI9nKGGycILvfIlu[XSnbImgO|DDqCViYYSgNlUxyqCwTR?= M17ye|I1PjZ6NUS3
ACP03 NFT5[ZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVTrOpJuOjVyL{O1NE82ODCwTR?= MkDVNlRp MWfk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHlib3[gZZBxem:6aX3heIVtgSB5MNMgKUBifCB{NUFCpI5O M2[3fVI1PjZ6NUS3
U87 GBM NX20[G1HT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHztT5AyODBxM{CwM|UxOCCwTR?= NULwSWtkPzJiaB?= MU[xNFAmKGW2aHHuc4w> M2C5[5Jm\HWlZYOgcYVidiClZXzsJI52dWKncjDifUA{OSxiNUSsJIFv\CB3ONMgKS=> NUPYW3R4OjR2NkS4OFE>
U87 GBM M3rXVWZ2dmO2aX;uJGF{e2G7 MVexNFAwPTByIF7t MUS0PEBp M2DDVFExOCViZYToZY5wdA>? MWPJcoR2[2W|IGPlcoV{[2WwY3WtUIls\SCDbITldoF1cW:wczDpckBPfWOuZXHyJG1wenCqb3zv[5k> M4TIeVI1PDZ2OESx
RPE NEXFZ|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHXfY0xNjJxMD60M|AvQC9zIN88US=> MUKyOE81QC95MjDo MXnEUXNQ NHfCS3JqdmirYnn0d{B1cGVicILvcIln\XKjdHnvckBjgSClZXzsJIN6[2ynIHHydoV{fA>? NWj1fnhWOjR2NU[2NFI>
HT29  M2LabWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\3WYgyQDBibl2= MU[3NkBp MXTJR|UxKG:oIEG4NEBvVQ>? NXLuUXNDOjR|NkiyOlU>
hMSCs MUHGeY5kfGmxbjDBd5NigQ>? MVO2MlI2KG6P NUnJXHYyOjRiaB?= NVLoXZM5TE2VTx?= MmTsd5Ri[mmuaYrld{BJcXO2b37lJGFk\XS7bHH0bY9vKGGwZDD0bIUhTXiycnXzd4lwdiCxZjDQcJVzcXCxdHXueEBI\W6ncx?= M2rwV|I1OzF{M{W2
Huh7  NIiyV2NHfW6ldHnvckBCe3OjeR?= NEXpRo4xNjFxMD61M|EvOCEQvF2= MXeyOIg> NYDDRoVHe3WycILld5NmeyC\VFjER|Ih\2WwZTDlfJBz\XO|aX;u M17BVFI1OjZ7Nkey
SKOV3 NXju[WhNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU[wMlA2NTJizszN MXKxNE8zPC92ODDo MV7EUXNQ NIjvSndu\WSrYYTld{Boem:5dHigZZJz\XO2IHnuJIEh[2:wY3XueJJifGmxbj2gZY5lKHSrbXWt[IVx\W6mZX70JI1idm6nch?= M{fD[lI1OjJ|OECx
A2780 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYqwMlA2NTJizszN MUSxNE8zPC92ODDo MmXKSG1UVw>? MkC0cYVlcWG2ZYOg[5Jwf3SqIHHydoV{fCCrbjDhJINwdmOnboTyZZRqd25vIHHu[EB1cW2nLXTldIVv\GWwdDDtZY5v\XJ? M4r2dlI1OjJ|OECx
SRA01/04  MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE[zSXoxNjJizszN NWLoPGxGPDhiaB?= NHTtfXlFVVOR M3eycpN2eHC{ZYPz[ZMh[2WubDDwdo9tcW[ncnH0bY9vKHSqcn;1[4ghe3WycILld5NqdmdidHjlJHBKO0txQXv0MEBxOziPQWDLJIFv\CCHUluxM|Ihe2mpbnHsbY5oKHCjdHj3ZZl{ Mm[yNlQyPTd6N{i=
HLEB3 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;QWm8xNjJizszN NVXVUGFSPDhiaB?= Mlq5SG1UVw>? MVzzeZBxemW|c3XzJINmdGxicILvcIln\XKjdHnvckB1cHKxdXfoJJN2eHC{ZYPzbY5oKHSqZTDQTVNMN0GtdDygdFM5VUGSSzDhcoQhTVKNMT:yJJNq\26jbHnu[{Bx[XSqd3H5dy=> M3XxTFI1OTV5OEe4
SRA01/04  M4XSSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4Sy[FAvPC9yLkig{txO NE\6Upo1QCCq M3rtRmROW09? M1PVOolv\HWlZYOgZ4VtdCCjcH;weI9{cXN? M3zZS|I1OTV5OEe4
HLEB3 Mnm4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXLPZEyOC52L{CuPEDPxE1? M2qwdFQ5KGh? MnrkSG1UVw>? MmjXbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? MXmyOFE2Pzh5OB?=
HCT116 NXi4dIRET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXjKT4ZxOC5{IN88US=> MWexNkBp M1L2SIVvcGGwY3XzJINmdGxiYYDvdJRwe2m|IHnu[JVk\WRiYomgdoFlcWG2aX;u NEHTT5EzPDF{MkKzNS=>
CA46 M3eyeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{SxNFMwPi9zMj:yOE81QCCwTR?= MnnIOFghcA>? M3H4dYlvcGmkaYTzJJRp\SClZXzsJJBzd2yrZnXyZZRqd25iYYSgNlQh[W6mIES4JI5OyqB? NXrjbGp[OjRyNkS5OVE>
PMNs NYXtW|diTnWwY4Tpc44hSXO|YYm= NHy1bGM{OCCwTR?= MXO0PEBp NYjUUHlLcW6qaXLpeJMh\W[oZYLvZ5l1d3OrczygTGRCSyCjY4Tpeol1gSCjbnSgVoFkKGGldHn2bZR6 MlHINlM6QDh4MUe=
H1299 NIr6bFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPhemMyyqEQvF5CpC=> MljGNlQwPDhxN{KgbC=> NGT6T2dmfGijbn;s NYH5THU3cW6lcnXhd4V{KGOnbHyg[IVifGhiYX\0[ZIhOjSq NUHFRmU6OjN7MU[2NFk>
A549 NYC2[|g4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2jCSVAvOjVxMD61M|Eh|ryP M3jLVFI1NzR6L{eyJIg> MWnleIhidm:u NVr2SXFFcW6qaXLpeJMhfGinIHPlcIwh\3Kxd4ToJIlvKGOxbnPlcpRz[XSrb36gZY5lKHSrbXWt[IVx\W6mZX70JI1idm6nch?= MX2yN|g3Pzl7MR?=
H1299 NFLXNWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHyNE4zPS9yLkWvNUDPxE1? MmT2NlQwPDhxN{KgbC=> M3\YZoV1cGGwb3y= NVjDenp6cW6qaXLpeJMhfGinIHPlcIwh\3Kxd4ToJIlvKGOxbnPlcpRz[XSrb36gZY5lKHSrbXWt[IVx\W6mZX70JI1idm6nch?= MXiyN|g3Pzl7MR?=
A549 NH7tepZCeG:ydH;zbZMhSXO|YYm= MX2wMlUwOSEQvF2= M{TzcFQ5KGh? MX;leIhidm:u Mle1bY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? MlTRNlM5Pjd7OUG=
H1299 MlnERZBweHSxc3nzJGF{e2G7 NEPnUY8xNjVxMTFOwG0> MmT0OFghcA>? MXXleIhidm:u MYPpcoR2[2W|IHPlcIwh[XCxcITvd4l{ NWr2WnpOOjN6Nke5PVE>
SUM149PT NVfze25kT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HtSFIwPy53L{GwJO69VQ>? MmLDOFghcA>? NVuwW2NTTE2VTx?= NHHMPIlqdmS3Y3XzJINmdGxiZHXheIgh[XRiMjFOwG0hcW6|ZX7zbZRqfmWueR?= MXuyN|c6OjZ|OB?=
SUM190PT MmrQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHaOVAwOTByL{K1NEBvVQ>? NWDBZlk1PDhiaB?= MkL5SG1UVw>? NYHGUGxLcW6mdXPld{Bk\WyuIHTlZZRpKGG2IEWwJI5OKHOnboPpeIl3\Wy7 MX2yN|c6OjZ|OB?=
HCT1 NXnkdYZvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\RNE4zNzFwMD:1MlAh|ryP MkDuNVIwOjRxM{[vOFghcA>? MWHpcoR2[2W|IHPlcIwh\GWjdHigbY4h[2:wY3XueJJifGmxbj2gZY5lKHSrbXWt[IVx\W6mZX70JI1idm6nch?= M33OSFI{PzdyMECw
Lovo NIH2TWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXmwMlIwOS5yL{WuNEDPxE1? MX:xNk8zPC9|Nj:0PEBp MVfpcoR2[2W|IHPlcIwh\GWjdHigbY4h[2:wY3XueJJifGmxbj2gZY5lKHSrbXWt[IVx\W6mZX70JI1idm6nch?= M3rtb|I{PzdyMECw
AGS M2PTTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;MNE4xOTVvMTFOwG0> MX63NkBp NF7TR4RqdmS3Y3XzJINmdGxiZHXheIgh[2:wY3XueJJifGmxbjDk[ZBmdmSnboTsfS=> M3HnSVI{PzR3MEK0
Huh7 Ml7kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkDmNUDPxE1? Mo[4NlQhcA>? MYHEUXNQ M4TMSpJm\HWlZYOgZYJwfXRiMkClJJZq[WKrbHn0feKh MVOyN|Y1Ozl|Mx?=
ECC1 NWm2XG5qTnWwY4Tpc44hSXO|YYm= NI[5d|Y2ODBibl2= M{XMXVUh\A>? MknBSG1UVw>? NVPlPXc{cW6mdXPld{BNOUODTdMg[ZhxemW|c3nvckBkdy22cnXheI1mdnRid3n0bEA2NUG8YVO= MVqyN|U{ODd4OR?=
HEC1A NYjlNVd3TnWwY4Tpc44hSXO|YYm= NUHOPIx3PTByIH7N NFLE[|k2KGR? M{Xu[WROW09? MnK2bY5lfWOnczDMNWNCVcLiZYjwdoV{e2mxbjDjc{11emWjdH3lcpQhf2m2aDC1MWF7[UN? M3L2cVI{PTNyN{[5
EN1 M4r2dWZ2dmO2aX;uJGF{e2G7 MWO1NFAhdk1? NVPSW|MyPSCm NIP4WWFFVVOR NHLtUJBqdmS3Y3XzJGwyS0GPwrDlfJBz\XO|aX;uJINwNXS{ZXH0cYVvfCC5aYToJFUuSXqjQx?= NYTFUHZSOjN3M{C3Olk>
MFE296 MonHSpVv[3Srb36gRZN{[Xl? Ml:4OVAxKG6P MkLzOUBl MUHEUXNQ MXXpcoR2[2W|IFyxR2FOyqCneIDy[ZN{cW:wIHPvMZRz\WG2bXXueEB4cXSqIEWtRZpiSw>? NGPGUnAzOzV|MEe2PS=>
HASMCs NYrKdWlPTnWwY4Tpc44hSXO|YYm= NGrTVo4xNTVyMDDuUS=> MkfuOkBl NFnsNJpld3ewLYLl[5Vt[XSnczD0bIUh\XiycnXzd4lwdiCxZjDIRWREKGGwZDDj[YxtKH[rYXLpcIl1gQ>? NVrlcpNkOjN3MUi0Olc>
U373 M3\GcWZ2dmO2aX;uJGF{e2G7 MVKwMlI2NzBwNT:xJO69VQ>? NHj5coIzPCCq MXrpcoNz\WG|ZYOgVHIuSiCneIDy[ZN{cW:wIHPvMZRz\WG2bXXueEB4cXSqIEXBfoFlSw>? M3jGSVI{PDd2MUex
ARN8  MnrxSpVv[3Srb36gRZN{[Xl? M171OlAvODVvMjFOwG0> NXz2[VRmOjRiaB?= MUPy[YR2[2W|IITo[UBqdmS3Y4Tpc44hd2ZicEWzMYRmeGWwZHXueEBo\W6nczDifUBPfXSuaX6tNy=> M2HSZlI{PDdyNUSw
MCF7 NGP2NYhHfW6ldHnvckBCe3OjeR?= MXOwMlA2NTJizszN MnTENlQhcA>? NXi2SZY5emWmdXPld{B1cGViaX7keYN1cW:wIH;mJJA2Oy2mZYDlcoRmdnRiZ3Xu[ZMh[nliToX0cIlvNTN? MX[yN|Q4ODV2MB?=
H1299  NUnifJVCTnWwY4Tpc44hSXO|YYm= MYewMlM{6oDVMdMgxtVO M1fZc|I1NzR6IHi= NX\Z[4E1TE2VTx?= NUe5e5JJcW6lcnXhd4V{KEVvY3HkbIVzcW5icILveIVqdiCuZY\lcJMh\G:|ZTDk[ZBmdmSnboTsfS=> NYe1UZU6OjN2NkG5O|U>
H1299 MXfGeY5kfGmxbjDBd5NigQ>? M3XHbVAvPSEQvF2= NUmzdW1IPDhiaB?= NGfXe2NFVVOR MnqxbY5pcWKrdIOgeIhmKG2rZ4LheI9zgSCyb4TlcpRq[WxiY3;tZolv\SC5aYToJJNqdGmkaX7pci=> NFe3eGkzOzR4MUm3OS=>
H1299 Mn\tSpVv[3Srb36gRZN{[Xl? NXjrWXA2OC53IN88US=> NFLwWYg1QCCq MkmzSG1UVw>? MVLpcohq[mm2czD0bIUhcW64YYPpeoVv\XO|wrCgZ49u[mmwZTD3bZRpKHOrbHnibY5qdg>? M2LWb|I{PDZzOUe1
MG-63  NVXYO2ZXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlW1NE4{KM7:TR?= NVnJWWRKOTJvOU[gbC=> NGLoWG1FVVOR NX7mToZpcW6qaXLpeJMhfGinIHPlcIwh\3Kxd4ToJINwNXS{ZXH0cYVvfCC5aYToJI1mfG[xcn3pci=> M4[zUVI{PDVzOEG3
LM8 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXraWHF5OC5|IN88US=> NEi2dY0yOi17NjDo MofXSG1UVw>? NWHiO5pocW6qaXLpeJMhfGinIHPlcIwh\3Kxd4ToJINwNXS{ZXH0cYVvfCC5aYToJI1mfG[xcn3pci=> MX6yN|Q2OThzNx?=
K562 M1fyTGZ2dmO2aX;uJGF{e2G7 MYmwMlUh|ryP MV:yOEBp MXnleIhidm:u NG\1dGpl\WO{ZXHz[ZMhfGinIHXufplu\SCjY4Tpeol1gSCxZjDISGFEeyClbz30doVifG2nboSge4l1cCCldYLjeY1qdg>? NY\yR5FWOjN2M{C5OVc>
HEL Ml[zSpVv[3Srb36gRZN{[Xl? NGPtUVgxNjVizszN MmOxNlQhcA>? MWnleIhidm:u M4LiboRm[3KnYYPld{B1cGViZX76fY1mKGGldHn2bZR6KG:oIFjERWN{KGOxLYTy[YF1dWWwdDD3bZRpKGO3cnP1cYlv NGHVdW0zOzR|MEm1Oy=>
HL60 MkjsRZBweHSxc3nzJGF{e2G7 NF;sfG4yKM7:TR?= MkjyNlQhcA>? MW\pcoR2[2W|wrDj[YxtKGSnYYTo M{[wcVI{PDByNUG5
KG1 MUHBdI9xfG:|aYOgRZN{[Xl? NX;KOGc2OSEQvF2= NUTlPXFJOjRiaB?= Mlv1bY5lfWOnc9MgZ4VtdCCmZXH0bC=> MnnpNlM1ODB3MUm=
Kazumi NWC5c2FYSXCxcITvd4l{KEG|c3H5 M1P3T|Eh|ryP NIfJToEzPCCq MUDpcoR2[2W|wrDj[YxtKGSnYYTo Mn6zNlM1ODB3MUm=
K562 Mn;PRZBweHSxc3nzJGF{e2G7 MkPQNUDPxE1? MYiyOEBp NIH6e29qdmS3Y3XzxsBk\WyuIHTlZZRp NU\V[JNPOjN2MEC1NVk>
THP1 M{PPfGFxd3C2b4Ppd{BCe3OjeR?= NXvqSoxGOSEQvF2= M13q[FI1KGh? MV;pcoR2[2W|wrDj[YxtKGSnYYTo NHTVOHEzOzRyMEWxPS=>
SH-SY5Y MlPYSpVv[3Srb36gRZN{[Xl? NX3ENXU3OjVyIH7N Mmm0NVYhcA>? NHvvTW5kcGGwZ3XzJIV5eHKnc4Ppc44heGG2dHXyckBw\iCpZX7ld{Bqdn[xbI\l[EBqdiClaH;s[ZN1\XKxbDDzfY51cGW|aYOsJJVxfGGtZTDhcoQh\W[obIX4 MYOyN|MzPjR{Mh?=
HEK293 M3jPNWZ2dmO2aX;uJGF{e2G7 MnHVNUDDvU4EoB?= M3LOXlE5KGkEoB?= M3raTolvcGmkaYTzJJRp\SCtYXzpdolvNTdvbXXkbYF1\WRicnXjdpVqfG2nboSgc4Yhe3mwcHjpcIlvNTFiYXfndoVo[XSnczDpcpRwKGGpZ4Lld49u\XN? NWLOcldvOjN{OES4OFg>
HTK NFG2fnFHfW6ldHnvckBCe3OjeR?= NXn4No44PDByIH7N M1vJSVczKGh? NX3SVZJFcW6qaXLpeJMhXEeILd8y5qCUUW6mdXPl[EBOgW:oaXLyc4Jt[XO2IFTp[oZmemWwdHnheIlwdg>? NH3WXXYzOzJ6NECwNi=>
HTK M3TObWZ2dmO2aX;uJGF{e2G7 MoXoNVAxNThyMH7N M3PZblczKGh? M3TSV4Jtd2OtczDUS2Yu|rMkgKPJcoR2[2WmIGLPV{BidmRiSELPNuKhSWOldX31cIF1cW:w MUmyN|I5PDByMh?=
Caco-2  M37i[GZ2dmO2aX;uJGF{e2G7 NWPHfpZPOSEEtV5CpC=> MYeyOEBp MYPk[YNz\WG|ZYOgV2VTXCCycn;0[YlvKGW6cILld5Nqd25? Mn;KNlMyQTVyN{C=
HeLa MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHmNVAxKG6P MV2yOEBp Ml;LSG1UVw>? M4XrWWlEPTBib3[gNVAxdk1? NF\1bGYzOzF4NUe0PC=>
HeLa NGO5bVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU[0NEBvVQ>? MX[0PEBp MXXEUXNQ NEnOVXdKSzVyIH;mJFQxdk1? M3mxSFI{OTZ3N{S4
HeLa MorWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1nwb|IxKG6P NVzHWYVHPzJiaB?= NIL6TIlFVVOR NETt[nFKSzVyIH;mJFIxdk1? NIS3XlYzOzF4NUe0PC=>
HeLa NY[wWlVwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rBc|ExNzNyL{WwJI5O MmD5O|IhcA>? MWHEUXNQ MorNbY5kemWjc3XzJJRp\SCwdX3i[ZIhd2ZiTV3QJEjPnM7qbTmgcI9{eyClZXzsd{Bld3OnIHTldIVv\GWwdHz5 NYniZm4{OjNzNkW3OFg>
MDA-MB-231 MoLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXKyOU01ODBibl2= NFnBfo41QCCq NGrBNFdKSzVyIH;mJFI3Oy5{bl5CpC=> MWKyN|A2PTF7OB?=
MCF-7  MlrHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW[yOU01ODBibl2= MlO2OFghcA>? Mo\WTWM2OCCxZjCyNlAvPG6P MnPiNlMxPTVzOUi=
ECC-1  NUHIW2J[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3K2c|ExOCCwTR?= MVyyOEBp M4j5e4V1cGGwb3y= Mn\3bY5kemWjc3XzJJRp\SCycn;wc5J1cW:wIH;mJIFxd3C2b4TpZ{BvfWOuZXmgeI8hOzVn M131flI{ODJ6OECz
HEC-1A MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnO1NVAxKG6P M4nGRVI1KGh? NGLDZ5pmfGijbn;s NXj5V|JmcW6lcnXhd4V{KHSqZTDwdo9xd3K2aX;uJI9nKGGyb4D0c5Rq[yCwdXPs[YkhfG9iM{ml MYeyN|AzQDhyMx?=
NHAC-kn MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlq5NVAwOTByL{WwNEBvVQ>? NFLPbIwyOiCq MVzEUXNQ MYjJR|UxKG:oIEWwNI5O MkH2NlMxOTd6N{G=
A549 M2Gyb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mkn2NlUxKG6P MnTZOk04OiCq Mlr3SG1UVw>? MWHjZZV{\XNiYTDndoVifGW{IHnubIljcXSxcomg[YZn\WO2IHPvcYJqdmVid3n0bEBVYFRib4Kg[ZJtd3Srbnni M3y1ZVIzQTl2N{iw
MG-63 NYfFXnRmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TnOlMxOCCwTR?= NW[4cpppOTJiaB?= NIf2PHhFVVOR MVnpcohq[mm2czD0bIUh[2WubDDndo94fGhidH:gPFYm MmjVNlI4QTl|M{i=
MG-63 M3rRXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVSzNFAhdk1? NFvWOJIzPCCq M1vxdWROW09? MmD6bY5pcWKrdIOgeIhmKGOnbHyg[5Jwf3SqIITvJFY4LQ>? NXXlfHFZOjJ5OUmzN|g>
MG-63 M4LnSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo[wN|AxKG6P M2HUR|Q5KGh? MmHISG1UVw>? MmrHbY5pcWKrdIOgeIhmKGOnbHyg[5Jwf3SqIITvJFU3LQ>? NXzDfXh{OjJ5OUmzN|g>
HL60  Mm\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HtRlE2OC1|NUCgcm0> MV2yOEBp NYPUdHFQcW6lcnXhd4V{KGOnbHygZZBweHSxc3nzxsB4cGWwIHPvcoNmdnS{YYTpc45{KGirZ3jldkB1cGGwIEK1NEBvVQ>? M3;3N|IzPzV|N{O5
U937 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXL3bnZMOTVyLUO1NEBvVQ>? M{KxOlI1KGh? MmXrbY5kemWjc3XzJINmdGxiYYDvdJRwe2m|wrD3bIVvKGOxbnPlcpRz[XSrb37zJIhq\2incjD0bIFvKDJ3MDDuUS=> MonPNlI4PTN5M{m=
SCC-6 NFvXdXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWeyNFAuOzJyMDDuUS=> Ml65NVIwOjRxNEigbC=> Ml21SG1UVw>? MXLpcohq[mm2czD0bIUheHKxbHnm[ZJifGmxbjDv[kBUS0NvNjDj[YxteyCrbjDhJIRwe2VvIHHu[EB1cW2nLXTldIVv\GWwdDDtZY5v\XJ? Mnn1NlI2PTJ|MkG=
U87  NVzzRldDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWCxNFAuOzByIH7n NHy0[|QzPCCq NInW[JdqdmirYnn0d{B1cGViY3XscEBoem:5dHigeI8hPzJnIDDheEAzODCwZx?= NXjsZ44zOjJ{N{C4OFk>
K562 MXPGeY5kfGmxbjDBd5NigQ>? MWSxJO69VQ>? M1ftclEzKGh? NIfQZo9FVVOR Mlrm[Y5p[W6lZYOgeIhmKGW6cILld5Nqd25ib3[gVnVPYDNiaX7keYNm\CCkeTC1MYF7[S2FZGK= NXn4WXk4OjJzN{mxPVg>
Reh M3HHZmZ2dmO2aX;uJGF{e2G7 MWWwMlMwOSEQvF2= NF7mbYsyOiCq NUOyNXVoTE2VTx?= M{CxeYVvcGGwY3XzJJRp\SCneIDy[ZN{cW:wIH;mJHJWVlh|IHnu[JVk\WRiYomgOU1igmFvQ3TS NX3xU4ZmOjJzN{mxPVg>

... Click to View More Cell Line Experimental Data

In vivo試験 Administration of Trichostatin A at 0.5 mg/kg for 4 weeks displays potent antitumor activity in the N-methyl-N-nitrosourea carcinogen-induced rat mammary carcinoma model, without any measurable toxicity at doses up to 5 mg/kg. [1] Single intraperitoneal doses of 10 mg/kg Trichostatin A in nontransgenic and spinal muscular atrophy (SMA) model mice results in increased levels of acetylated H3 and H4 histones and modest increases in survival motor neuron (SMN) gene expression. Administration of Trichostatin A at 10 mg/kg/day improves survival, attenuates weight loss, and enhances motor behavior in the SMA model mice. [5]
臨床試験
特集

プロトコル (参考用のみ)

キナーゼアッセイ:

[1]

In vitro HDAC activity Total cellular extracts are prepared from each breast cancer cell line (MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, or SK-BR-3). A 20 μL crude cell extract (~2.5 ×105 cells), in the presence of varying concentrations of Trichostatin A in 0.1% (v/v) ethanol or 0.1% (v/v) ethanol as vehicle control, are incubated for 60 minutes at 25 °C with 1 μL (~1.5 × 106 cpm) of [3H]acetyl-labeled histone H4 peptide substrate (NH2-terminal residues 2-20) that has been acetylated with [3H]acetic acid, sodium salt (3.7 GBq/mmol) by an in vitro incorporation method. Each 200 μL reaction is quenched with 50 μL of 1 M HCl/0.16 M acetic acid and extracted with 600 μL of ethyl acetate, and released [3H]acetate is quantified by scintillation counting. IC50 values are determined graphically using nonlinear regression to fit inhibition data to the appropriate dose-response curve.

細胞アッセイ:

[1]

細胞株 MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, and SK-BR-3
濃度 Dissolved in absolute ethanol, final concentrations ~10 μM
反応時間 96 hours
実験の流れ

Cells are exposed to various concentrations of Trichostatin A for 96 hours. After treatment, cell proliferation is estimated using the sulforhodamine B colorimetric assay. Cell viability is determined by trypan blue exclusion.

動物実験:

[1]

動物モデル Inbred virgin female (Ludwig/Wistar/Olac) rats bearing tumors induced with NMU
製剤 Dissolved in DMSO
投薬量 ~5 mg/kg/day
投与方法 Injection s.c.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)0.020.151.80.40.0810312
Body Surface Area (m2)0.0070.0250.150.050.020.50.240.6
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

参考

化学情報

Download Trichostatin A (TSA) SDF
分子量 302.4
化学式

C17H22N2O3

CAS No. 58880-19-6
保管 3年-20℃
2年-80℃in solvent
別名 N/A
溶解度 (25°C) * In vitro DMSO 23 mg/mL (76.05 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 1% DMSO+30% polyethylene glycol+1% Tween 80, pH 4 6 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 (R,2E,4E)-6-(4-(dimethylamino)benzoyl)-N-hydroxy-4-methylhepta-2,4-dienamide

文献中の引用 (21)

技術サポート&よくある質問(FAQ)

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)

他の質問がある場合は、お気軽くお問合せください。

* 必須

Related HDAC 阻害剤

  • LMK-235

    LMK-235は一種のHDAC4とHDAC5選択性阻害剤で、IC50値が11.9 nM と 4.2 nMに分かれます。

  • CAY10603

    CAY10603は一種の有効的で、選択性的なHDAC6阻害剤で、IC50値が2 pMになって、HDAC6に作用する選択性はHDACsに作用する選択性より200倍以上が高くなります。

  • 4SC-202

    4SC-202は一種の選択性I型HDAC阻害剤で、HDAC1、HDAC2とHDAC3に作用する時のIC50値が1.20 μM、1.12 μMと0.57 μMそれぞれに分かれて、Lysine specific demethylase 1 (LSD1)にも抑制活性を表します。臨床1期。

  • HPOB

    HPOBは一種の有効的で、選択性HDAC6阻害剤で、IC50値が56 nMになって、HDAC6に作用する選択性は他のHDACsに作用する選択性より30倍以上が高くなります。

  • Panobinostat (LBH589)

    Panobinostat (LBH589) は一種の新たで、広範なHDAC阻害剤で、無細胞試験でIC50値が5 nMです。臨床3期。

  • Vorinostat (SAHA, MK0683)

    Vorinostat (suberoylanilide hydroxamic acid, SAHA)は一種のHDAC阻害剤で、無細胞試験でIC50値が約10 nMです。

  • Entinostat (MS-275)

    Entinostat (MS-275)はHDAC1とHDAC3を強く抑制して、無細胞試験でIC50値が0.51μMと1.7μMに分かれて、抑制作用がHDACs 4/6/8/10より良くなリます。臨床3期。

  • Romidepsin (FK228, Depsipeptide)

    Romidepsin (FK228, Depsipeptide)は一種の有効なHDAC1とHDAC2阻害剤で、無細胞試験でIC50値が36 nMと47 nMに分かれます。

    Features:More effective than other classical HDAC inhibitors such as TSA, TPX, and butyrate.

  • RGFP966

    RGFP966は一種のHDAC3阻害剤で、無細胞試験でIC50値が0.08μMになって、HDAC3に作用する選択性が他のHDACに作用する選択性より200倍以上高くなります。

最近チェックしたアイテム

Tags: Trichostatin A (TSA)を買う | Trichostatin A (TSA)供給者 | Trichostatin A (TSA)を購入する | Trichostatin A (TSA)費用 | Trichostatin A (TSA)生産者 | オーダーTrichostatin A (TSA) | Trichostatin A (TSA)代理店
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
お問い合わせ